The effects of opioids and opioid analogs on animal and human endocrine systems
- PMID: 19903933
- PMCID: PMC2852206
- DOI: 10.1210/er.2009-0009
The effects of opioids and opioid analogs on animal and human endocrine systems
Abstract
Opioid abuse has increased in the last decade, primarily as a result of increased access to prescription opioids. Physicians are also increasingly administering opioid analgesics for noncancer chronic pain. Thus, knowledge of the long-term consequences of opioid use/abuse has important implications for fully evaluating the clinical usefulness of opioid medications. Many studies have examined the effect of opioids on the endocrine system; however, a systematic review of the endocrine actions of opioids in both humans and animals has, to our knowledge, not been published since 1984. Thus, we reviewed the literature on the effect of opioids on the endocrine system. We included both acute and chronic effects of opioids, with the majority of the studies done on the acute effects although chronic effects are more physiologically relevant. In humans and laboratory animals, opioids generally increase GH and prolactin and decrease LH, testosterone, estradiol, and oxytocin. In humans, opioids increase TSH, whereas in rodents, TSH is decreased. In both rodents and humans, the reports of effects of opioids on arginine vasopressin and ACTH are conflicting. Opioids act preferentially at different receptor sites leading to stimulatory or inhibitory effects on hormone release. Increasing opioid abuse primarily leads to hypogonadism but may also affect the secretion of other pituitary hormones. The potential consequences of hypogonadism include decreased libido and erectile dysfunction in men, oligomenorrhea or amenorrhea in women, and bone loss or infertility in both sexes. Opioids may increase or decrease food intake, depending on the type of opioid and the duration of action. Additionally, opioids may act through the sympathetic nervous system to cause hyperglycemia and impaired insulin secretion. In this review, recent information regarding endocrine disorders among opioid abusers is presented.
Figures
Similar articles
-
The impact of opioids on the endocrine system.Clin J Pain. 2009 Feb;25(2):170-5. doi: 10.1097/AJP.0b013e3181850df6. Clin J Pain. 2009. PMID: 19333165
-
Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews.Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD012509. doi: 10.1002/14651858.CD012509.pub2. Cochrane Database Syst Rev. 2017. PMID: 29084357 Free PMC article.
-
Opioids for cancer pain - an overview of Cochrane reviews.Cochrane Database Syst Rev. 2017 Jul 6;7(7):CD012592. doi: 10.1002/14651858.CD012592.pub2. Cochrane Database Syst Rev. 2017. PMID: 28683172 Free PMC article.
-
Parenteral opioids for maternal pain management in labour.Cochrane Database Syst Rev. 2018 Jun 5;6(6):CD007396. doi: 10.1002/14651858.CD007396.pub3. Cochrane Database Syst Rev. 2018. PMID: 29870574 Free PMC article.
-
Supervised dosing with a long-acting opioid medication in the management of opioid dependence.Cochrane Database Syst Rev. 2017 Apr 27;4(4):CD011983. doi: 10.1002/14651858.CD011983.pub2. Cochrane Database Syst Rev. 2017. PMID: 28447766 Free PMC article.
Cited by
-
Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy.BMJ Open. 2013 Jun 20;3(6):e002856. doi: 10.1136/bmjopen-2013-002856. BMJ Open. 2013. PMID: 23794541 Free PMC article.
-
Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial.Pain. 2015 Feb;156(2):280-288. doi: 10.1097/01.j.pain.0000460308.86819.aa. Pain. 2015. PMID: 25599449 Free PMC article. Clinical Trial.
-
Association of Receiving Multiple, Concurrent Fracture-Associated Drugs With Hip Fracture Risk.JAMA Netw Open. 2019 Nov 1;2(11):e1915348. doi: 10.1001/jamanetworkopen.2019.15348. JAMA Netw Open. 2019. PMID: 31722031 Free PMC article.
-
Opioidergic Agents as Antidepressants: Rationale and Promise.CNS Drugs. 2019 Jan;33(1):9-16. doi: 10.1007/s40263-018-0584-7. CNS Drugs. 2019. PMID: 30430396 Review.
-
Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation.Int J Mol Sci. 2021 Oct 24;22(21):11465. doi: 10.3390/ijms222111465. Int J Mol Sci. 2021. PMID: 34768894 Free PMC article. Review.
References
-
- National Institute on Drug Abuse 2008 Clinical trials network— research. Retrieved July 22, 2009. http://www.nida.nih.gov/CTN/Research.html
-
- Hoffmann NG, Olofsson O, Salen B, Wickstrom L 1995 Prevalence of abuse and dependency in chronic pain patients. Int J Addict 30:919–927 - PubMed
-
- Manchikanti L 2007 National drug control policy and prescription drug abuse: facts and fallacies. Pain Physician 10:399–424 - PubMed
-
- 2007 The NSDUH Report: patterns and trends in nonmedical prescription pain reliever use 2002 to 2005. Rockville, MD: Substance Abuse and Mental Health Services Administration
-
- Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE 2008 Monitoring the future national results on adolescent drug use: overview of key findings, 2007. Bethesda, MD: National Institute on Drug Abuse
Publication types
MeSH terms
Substances
Grants and funding
- U54 HD41748/HD/NICHD NIH HHS/United States
- R01 DA016682/DA/NIDA NIH HHS/United States
- G21 RR03026/RR/NCRR NIH HHS/United States
- R01 DA014659/DA/NIDA NIH HHS/United States
- R01 DA14659/DA/NIDA NIH HHS/United States
- R01 DA021274/DA/NIDA NIH HHS/United States
- R01 DA16682/DA/NIDA NIH HHS/United States
- U54 HD041748/HD/NICHD NIH HHS/United States
- U54 RR14616/RR/NCRR NIH HHS/United States
- G12 RR003026/RR/NCRR NIH HHS/United States
- U54 RR014616/RR/NCRR NIH HHS/United States
- R25 DA033613/DA/NIDA NIH HHS/United States
- R24 DA017298/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical